Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated Plans Approved for use through 3/31/2007. OMB 0651-0021	end Checkochechos Coparing a Silvingsion Muhde 35 (C. Edill E. i.						
U. S. PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER						
U.S. DEPARTMENT OF COMMERCE	21613P						
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)						
CONCERNING A FILING UNDER 35 U.S.C. 371	10/586976						
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED						
PCT/US2005/001344 18 January 2005	20 January 2004						
TITLE OF INVENTION ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES							
APPLICANT(S) FOR DO/EO/US							
Guo Q. Shi, Peter T. Meinke, James F. Dropinski, Yong Zhang							
Applicant herewith submits to the United States Designated/Elected O other information:	ffice (DO/EO/US) the following items and						
1. X This is a FIRST submission of items concerning a filing under 35	U.S.C. 371.						
2. This is a SECOND or SUBSEQUENT submission of items conce	erning a filing under 35 U.S.C. 371.						
3. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below.							
4. The US has been elected (PCT Article 31).							
5. X A copy of the International Application as filed [35 U.S.C. 371(c)	A copy of the International Application as filed [35 U.S.C. 371(c)(2)]						
a is attached hereto (required only if not communicated by the	a. is attached hereto (required only if not communicated by the International Bureau).						
b. has been communicated by the International Bureau.	b. has been communicated by the International Bureau.						
	c. X is not required, as the application was filed in the United States Receiving Office (RO/US).						
6. An English language translation of the International Application a a. is attached hereto	in a sugardar and an arrangement of the international representation as mode [55 0.5.0. 571(0)(2)].						
a. is attached hereto b. has been previously submitted under 35 U.S.C. 154(d)(4).							
7. Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]. a. are attached hereto (required only if not communicated by the International Bureau).							
b. have been communicated by the International Bureau.							
c. have not been made; however, the time limit for making suc							
d. A have not been made and will not be made.							
8. An English language translation of the amendments to the claims u	under PCT Article 19 [35 U.S.C. 371(c)(3)].						
9. An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].							
10. An English language translation of the annexes of the International Article 36 [35 U.S.C. 371(c)(5)].							
Items 11 to 20 below concern other document(s) or information includ 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98							
11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98 12. An assignment document for recording. A separate cover sheet in							
is included.	compliance with 57 Gr R 5.25 and 5.51						
	X A preliminary amendment.						
14. An Application Data Sheet under 37 CFR 1.76.							
15. A substitute specification. 16. A power of attorney and/or change of address letter							
The state of the s							
 7. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 8. A second copy of the published International Application under 35 U.S.C.154(d)(4). 							
19. A second copy of the English language translation of the internation							
20. Other items or information:	.m. approacion ander 33 0.3.0.137(a)(7).						

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated Received Diffice DO/ED/US) Concerning a Submission Under 35 U.S.C. 371"

Annowed for use through 3/31/2007. OMB 0651-0021

U.S. APPLI	CATION N	O. (If kno	wn, see 37 CE	R 149 &	INTERN	IATIONAL APPLICATION NO) .		ATTORNEY'S DOC	KET NUMBER
	1	ון נו	wn, see 37 CE	70	PCT/U	S2005/001344			21613P	
			submitted:		<u> </u>				CALCULATIONS	PTO USE ONLY
21.	Basic nati	ional fee						\$300	\$300.00	
22.		•	37 CFR 1.49							
						preliminary examination rep PCT Article 33(1)-(4)		\$0		
All other si									\$200.00	
1 -			R 1.492(b))							
						inary examination report pro				
						onal application to the USP			\$400.00	
International	al Search R	eport pr	epared by an	ISA other	than the	US and provided to the Offi	ce or		\$400.00	
1										
All other sit	uations					TOTAL OI			\$900.00	·
						er over 100 sheets (excluding	ig seque	nce listing or	\$200.00	
	uter programor or fraction			electronic n	nedium).	The fee is \$250 for each ad	lditional	50 sheets of		
Total Sh	eets	Extra	Sheets			additional 50 or fraction RATE				
						to a whole number)	-	 		A
49	- 100 =	0	/50	0	=	0	X	\$250.00	\$0.00	·
	of \$130.0 0 ite [37 CFR			ath or decla	ration la	ter than 30 months from the	earliest	claimed		
CLAIMS	ite 137 CI is	(1.4)2(NUMBER	FILED		NUMBER EXTRA		RATE		
Total Claim	ıs			17	- 20 =	0	x	\$50.00	\$0.00	
Independent	t Claims			1	- 3 =	0	x	\$200.00	\$0.00	
MULTIPLI	E DEPEND	ENT C	LAIM(S) (if a	applicable)			+	\$360.00		
TOTAL OF ABOVE CALCULATIONS (SUBTOTAL) =							\$900.00			
Processing	foo of \$120					•	d1:	4		
claimed price			_	English u	ansiation	later than 30 months from	ine earm	est +		
TOTAL NATIONAL FEE =							=	\$900.00		
						The assignment must be			-	
accompan	ied by an a	ppropria	ite cover shee	et (37 CFR	3.28, 3.3	31).\$40.00 per property. TOTAL FEES ENCL	OSED	+ =		
						TOTAL FEES ENCL	OSED		\$900.00	
									Amount to be refunded:	
									Amount to be	
						· .			charged:	
а. 🗀	A check	in the	amount of S	S		to cover the above fees i	s enclo	sed.		
b. 🔀			ny Deposit py of this sh			$\frac{2755}{1}$ in the amount of $\frac{$9}{1}$	900.00	to	cover the above fees.	
	-	_				harge any additional fees	which	may be requ	ired or credit any	
c. 🔼	overpay	ment to	the Depos	it Accoun	t No. <u>13</u>	-2755. A duplicate copy	of this	sheet is encl	osed.	
						CFR 1.494 or 1.495 has			ition to revive [37 CF	R 1.137(a) or
(b)] must	be filed a	and gra	anted to res	store the	Interna	tional Application to per	nding s	tatus.		
SEND.	ALL COR	RESPO	ONDENCE	TO:						
Cust	tomer No.	00021	0			^				
MERCK & CO., INC.										
Patent Department, RY60-30 P.O. Box 2000 SIGNATURE										
126 Eas	st Lincoln					S	IGNAT	UKE		
Rahway	y, New Jer	sey 07	065-0970			Ja	mes L.	McGinnis		
DATE	July 10	2006				N	IAME	-		
	July 19,		0641		-	34	1,387			
PHONE #: (732) 594-0641 REGISTRAT							RATION NU	JMBER		

10/586976 IAP6 Rec'd PCT/PTO 19 JUL 2006

Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Attorney Docket No.:	21613
International Appln No.:	PCT/US2005/001344
International Filing Date:	18 January 2005
Priority Date:	20 January 2004
Title:	ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES
Inventors:	Guo Q. Shi, Peter T. Meinke, James F. Dropinski, Yong Zhang

MAILED BY Klithoushi DATE 7-19-06